The coronavirus disease 2019(COVID-19)pandemic has profoundly impacted liver transplant(LT)activity across the world,with notable decreases in the number of donations and procedures in most Western countries,in partic...The coronavirus disease 2019(COVID-19)pandemic has profoundly impacted liver transplant(LT)activity across the world,with notable decreases in the number of donations and procedures in most Western countries,in particular throughout the first wave.The cumulative incidence of COVID-19 in LT recipients(with estimates ranging from 0.34%to 1.56%)appears to be at least comparable to that observed for the general population.Clinical and radiological features at presentation are also similar to non-transplant patients.The risk of death among LT recipients requiring hospital admission is high(from 12% to 19%),although some authors have suggested that overall mortality may be actually lower compared to the general non-transplant population.It is likely that these poor outcomes may be mainly influenced by the older age and higher comorbidity burden of LT recipients,rather than by the transplant status itself.In fact,it has been hypothesized that post-transplant immunosuppression would exert a protective role,with special focus on tacrolimus-containing regimens.There is scarce evidence to guide the optimal management of post-transplant COVID-19 and the use of antiviral or immunomodulatory therapies,although both clinical practice and guidelines support the dose reduction or withdrawal of anti-proliferative agents such as mofetil mycophenolate.Preliminary reports suggest that the antibody response to messenger RNA vaccines is significantly impaired as compared to non-immunocompromised individuals,in line with other transplant populations.Finally,it is foreseeable that the future will be conditioned by the emerging variants of severe acute respiratory syndrome coronavirus 2 with increased transmissibility among LT recipients.展开更多
文摘The coronavirus disease 2019(COVID-19)pandemic has profoundly impacted liver transplant(LT)activity across the world,with notable decreases in the number of donations and procedures in most Western countries,in particular throughout the first wave.The cumulative incidence of COVID-19 in LT recipients(with estimates ranging from 0.34%to 1.56%)appears to be at least comparable to that observed for the general population.Clinical and radiological features at presentation are also similar to non-transplant patients.The risk of death among LT recipients requiring hospital admission is high(from 12% to 19%),although some authors have suggested that overall mortality may be actually lower compared to the general non-transplant population.It is likely that these poor outcomes may be mainly influenced by the older age and higher comorbidity burden of LT recipients,rather than by the transplant status itself.In fact,it has been hypothesized that post-transplant immunosuppression would exert a protective role,with special focus on tacrolimus-containing regimens.There is scarce evidence to guide the optimal management of post-transplant COVID-19 and the use of antiviral or immunomodulatory therapies,although both clinical practice and guidelines support the dose reduction or withdrawal of anti-proliferative agents such as mofetil mycophenolate.Preliminary reports suggest that the antibody response to messenger RNA vaccines is significantly impaired as compared to non-immunocompromised individuals,in line with other transplant populations.Finally,it is foreseeable that the future will be conditioned by the emerging variants of severe acute respiratory syndrome coronavirus 2 with increased transmissibility among LT recipients.
